• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Modulating Transposable Genetic Elements Emerges as Dual Strategy Across Diverse Diseases

by
November 12, 2026
in Health
Reading Time: 5 mins read
0
Modulating Transposable Genetic Elements Emerges as Dual Strategy Across Diverse Diseases

Modulating Transposable Genetic Elements Emerges as Dual Strategy Across Diverse Diseases

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive review of genomic regulation reveals that transposable elements, long regarded as inert evolutionary remnants across the human genome, represent active biological regulators whose dysregulation directly fuels chronic inflammation, while their controlled reactivation offers unexpected therapeutic opportunities in oncology and regenerative medicine. These mobile repetitive sequences, encompassing autonomous long interspersed nuclear elements, non-autonomous short interspersed nuclear elements, and endogenous retroviruses, constitute a substantial proportion of human genetic material. LINE-1 elements alone make up approximately 20 percent of the genome, retaining the machinery necessary for autonomous mobilization via target-primed reverse transcription, whereas human endogenous retroviruses account for roughly 8 percent. While retrotransposition has historically been viewed primarily through the lens of insertional mutagenesis, accumulating evidence indicates that the primary pathogenic mechanism in non-cancer pathologies is transcriptional derepression, leading to the cytosolic accumulation of immunostimulatory RNAs, double-stranded RNA structures, and reverse-transcribed complementary DNA intermediates.

Under physiological conditions, the activity of transposable elements is stringently suppressed through multilayered epigenetic frameworks, most notably sequence-specific binding by KRAB zinc-finger proteins, targeted recruitment of TRIM28 co-repressor complexes, and SETDB1-dependent deposition of repressive histone H3 lysine 9 trimethylation marks, supplemented by DNA methylation, PIWI-interacting RNAs in germline tissues, and the surveillance functions of the HUSH complex. When these defensive checkpoints fail or when upstream RNA decay machineries such as the nuclear exosome targeting complex are compromised, aberrantly expressed transposable transcripts accumulate outside the nucleus. These sequences mimic viral infections, engaging pattern-recognition receptors including RIG-I, melanoma differentiation-associated protein 5, and protein kinase R for double-stranded RNA, as well as the cyclic GMP-AMP synthase and stimulator of interferon genes pathway for cytoplasmic DNA species. Activation of these cytosolic sensors converges on nuclear factor kappa B and interferon regulatory factors, generating a persistent type I interferon cascade and driving sterile, chronic inflammation.

In neurodegenerative disorders, loss of repressive heterochromatin leads to pronounced transposable element activation that directly accelerates tissue damage and cognitive impairment. In Alzheimer’s disease, elevated transposable element expression occurs in post-mortem brain biopsies, predominantly localized to microglial compartments, where pathological tau accumulation promotes heterochromatin loss and depletes protective piRNA populations. Experimental targeted overexpression of LINE-1 in the murine cerebellum was sufficient to induce Purkinje cell dysfunction, severe neurodegeneration, and progressive ataxia, demonstrating that retroelement activation can act as an initiating pathogenic driver rather than an incidental byproduct. Retrospective epidemiological investigations across human cohorts reveal that sustained treatment with nucleoside reverse transcriptase inhibitors correlates with a 4 to 13 percent reduction in Alzheimer’s risk per additional year of drug exposure, while early pilot clinical evaluations indicate that lamivudine treatment reduces neuroinflammatory biomarkers and alters amyloid-related parameters.

Parallel neurodegenerative investigations in amyotrophic lateral sclerosis have implicated envelope proteins and transcripts from HERV-K and LINE-1 as toxic drivers regulated by the RNA-binding protein TDP-43, whose nuclear depletion triggers widespread transposable derepression. In affected patients, HERV-K envelope proteins are detectable in cortical neurons, cerebrospinal fluid, and neuronal extracellular vesicles, correlating closely with disease severity and driving neurotoxic neurite retraction alongside pro-inflammatory cytokine secretion from B cells. While an initial phase II clinical study combining abacavir, lamivudine, and dolutegravir demonstrated reductions in HERV-K expression accompanied by slower progression trends in virological responders, the subsequent global phase III Lighthouse II trial enrolling over 400 participants was terminated early in April 2025 after a planned interim analysis demonstrated no overall survival benefit, highlighting the biological complexity and indicating that broader retrospective associations require precise, prospective patient stratification based on baseline retroelement activity.

Autoimmune conditions provide further direct evidence of immune pathology instigated by transposable element transcripts escaping cytosolic surveillance. In systemic lupus erythematosus and Sjögren’s syndrome, elevated LINE-1 expression in neutrophils and renal or salivary biopsies correlates with marked DNA hypomethylation and potent type I interferon activation, prompting active clinical investigations into whether adjuvant abacavir and lamivudine can durably quiet inflammatory signatures. In monogenic interferonopathies such as Aicardi-Goutières syndrome, inherited deficiencies in nucleases like TREX1, SAMHD1, or ADAR1 prevent the enzymatic clearance of retroelement reverse transcription products, resulting in massive accumulation of cytosolic DNA intermediates and relentless neuroinflammation. Interventional trials utilizing triple NRTI regimens achieved measurable reductions in interferon biomarkers, although these responses remained transient, rebounding sharply after therapy cessation or suffering from compliance limitations in pediatric cohorts.

In metabolic pathology, dietary stress, cellular senescence, and chromatin remodeling converge to provoke retroelement expression across critical metabolic organs. In models of metabolic dysfunction-associated steatotic liver disease, lipid-induced stress provokes LINE-1 derepression within hepatocytes, establishing chronic interferon signaling; targeted sequence-specific silencing using antisense oligonucleotides restored chromatin structure, suppressed inflammation, and attenuated hepatic fibrosis in vivo. Large-scale observational analyses covering tens of thousands of individuals have demonstrated that exposure to reverse transcriptase inhibitors is associated with a 50 percent lower risk of developing prediabetes and a 27 percent reduced risk of progressing to type 2 diabetes. However, clinical implementation requires careful discrimination among therapeutic classes, as specific non-nucleoside inhibitors like efavirenz induce pancreatic beta-cell toxicity and mitochondrial distress, while certain nucleoside inhibitors disrupt osteocyte biology and bone mineral density.

In oncology, transposable elements occupy a functional duality, operating both as genomic mutagens and as unique substrates for immunotherapeutic sensitization. Somatic LINE-1 mobilization occurs in approximately 35 percent of human tumors, disrupting tumor suppressors and fostering structural rearrangements, while onco-exaptation repurposes dormant retrotransposon promoters to drive aberrant oncogenic programs. Conversely, pharmacological disruption of epigenetic repression via DNA methyltransferase inhibitors and histone deacetylase inhibitors selectively induces a state of viral mimicry in neoplastic cells. Derepressed inverted-repeat Alu elements and endogenous retroviruses accumulate immunogenic double-stranded RNA, triggering MAVS- and STING-dependent signaling that transforms immunologically cold tumors into inflamed environments enriched with CD8-positive tumor-infiltrating lymphocytes, an approach successfully validated in clinical trials combining decitabine, azacitidine, or guadecitabine with checkpoint inhibitors like pembrolizumab.

Beyond viral mimicry and innate immune signaling, retroelement derepression creates a rich reservoir of shared tumor neoantigens that bypass the high interpatient heterogeneity of conventional somatic mutations. Proteogenomic evaluations across 33 distinct cancer indications revealed extensive tumor-selective presentation of retroelement-chimeric transcripts and envelope peptides on major histocompatibility complex class I molecules, with computational modeling projecting that vaccines targeting 20 recurrent chimeric proteins could achieve over 75 percent coverage across 27 cancer indications. Clinical trials are already evaluating adoptive cell modalities, including a completed 17-patient phase I trial utilizing autologous T cells engineered with T cell receptors specific for an HLA-A*11:01-restricted HERV-E antigen in clear cell renal cell carcinoma, pointing toward broadly applicable, off-the-shelf immunotherapies derived from non-coding genomic sequences.

Emerging research underscores that transient transposable element activation is not purely deleterious, functioning physiologically during wound healing, tissue repair, and stem cell reprogramming. Post-injury transcriptomic spikes of transposable element expression occur across regenerating species and during mammalian bone fracture healing, where LINE-1 double-stranded RNA engages protein kinase R in osteoblasts to stimulate mineralized matrix deposition independent of reverse transcriptase activity or classical cGAS-STING sensing. Similarly, synthetic double-stranded RNA analogs like poly(I:C) and STING agonists accelerate cutaneous re-epithelialization, enhance mesenchymal stem cell immunomodulation, and promote spontaneous axonal regeneration following nerve injury, demonstrating that calibrated, temporally restricted innate activation is essential for wound resolution, whereas persistent activation leads to senescence-associated secretomes and tissue fibrosis.

The therapeutic translation of retroelement biology ultimately faces critical technical hurdles, as mapping short-read sequencing data across highly repetitive loci obscures element-specific contributions, and transcript abundance does not reliably correlate with cytoplasmic accumulation or peptide presentation. Because retrotransposon expression rises universally during chronological aging due to progressive heterochromatin erosion, establishing whether an observed transposable signal reflects a disease-specific driver or normal age-related drift remains an essential requirement for proper patient stratification. Developing locus-specific epigenetic editing tools using catalytically inactive Cas9 platforms, alongside selective small-molecule inhibitors and targeted oligonucleotide delivery vehicles, will determine whether modulating these pervasive repetitive sequences can safely resolve chronic human pathologies.

Subject of Research: Therapeutic modulation of human transposable elements in cancer, neurodegeneration, autoimmunity, metabolic disorders, and aging

Article Title: The therapeutic potential of transposable element activity modulation

Article References: Morelli, G., D’Onghia, M., Mangiavacchi, A., & Orlando, V. (2026). The therapeutic potential of transposable element activity modulation. EMBO Molecular Medicine, 18(11), 4200-4226. https://doi.org/10.1038/s44321-026-00528-z

Image Credits: AI Generated

DOI: 10.1038/s44321-026-00528-z

Keywords: transposable elements, retrotransposons, LINE-1, HERV, reverse transcriptase inhibitors, lamivudine, efavirenz, interferon response, cGAS-STING, viral mimicry, epigenetic therapy, cancer immunotherapy, Alzheimer's disease, amyotrophic lateral sclerosis, Aicardi-Goutieres syndrome, systemic lupus erythematosus, type 2 diabetes, tissue repair

News Source: Juliet Wilcox. (November 12, 2026). Modulating Transposable Genetic Elements Emerges as Dual Strategy Across Diverse Diseases. Scienmag.

Tags: Aicardi-Goutieres syndromeAlzheimer's diseaseamyotrophic lateral sclerosisCancer immunotherapycGAS-STINGefavirenzepigenetic therapyHERVinterferon responselamivudineLINE-1retrotransposonsreverse transcriptase inhibitorssystemic lupus erythematosustissue repairtransposable elementsType 2 diabetesviral mimicry
Share12Tweet7Share2ShareShareShare1

Related Posts

Continuous Wearable Monitoring May Optimize Postoperative Patient Care Pathways

Continuous Wearable Monitoring May Optimize Postoperative Patient Care Pathways

November 17, 2026
FOXR2 and Metabolic Pathway Proteins Correlate With Ovarian Carcinoma Progression

FOXR2 and Metabolic Pathway Proteins Correlate With Ovarian Carcinoma Progression

November 17, 2026

Aortic Dissection Triggers Severe Hypoxemia Through Cardiac Shunt in Rare Case

November 17, 2026

Preoperative CRP Outperforms Symptom Duration in Predicting Severe Acute Cholecystitis Surgical Difficulty

November 17, 2026

POPULAR NEWS

  • Engineered Myeloid Progenitor Platform Overcomes Allogeneic Barriers in CNS Tumors

    Engineered Myeloid Progenitor Platform Overcomes Allogeneic Barriers in CNS Tumors

    29 shares
    Share 12 Tweet 7
  • Physician Specialty Distribution Lags Behind Global Demographic Aging Trends

    29 shares
    Share 12 Tweet 7
  • Rapid In Planta Citrus Transformation System Enables Efficient Genome Editing

    29 shares
    Share 12 Tweet 7
  • Simulated Reinforcement Learning Model Improves 4G LTE Handover Success and Reliability

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Continuous Wearable Monitoring May Optimize Postoperative Patient Care Pathways

Review Details Fungal Volatile 6-PP Biosynthesis and Roles in Sustainable Crop Protection

FOXR2 and Metabolic Pathway Proteins Correlate With Ovarian Carcinoma Progression

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.